That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...
Moderna (MRNA) ended the recent trading session at $51.30, demonstrating a -1.54% change from the preceding day's closing price. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the ...
Moderna (NasdaqGS:MRNA) reported positive Phase 3 clinical data for its investigational influenza vaccine mRNA-1010 and RSV ...
YieldMax MRNA Option Income Strategy ETF is rated a Sell due to heightened downside risk and overvalued pipeline optimism.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it ...
The Centers for Disease Control and Prevention (CDC) reportedly delayed the publication of its report detailing the benefits ...
A public health expert breaks down the details of the CDC delaying reporting of COVID-19 vaccine benefits, including study ...
As a result, since the start of the year, two formerly down-and-out stocks in these industries are outperforming the S&P 500.
Could this player be heading into a new era of growth?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results